Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Annual Shareholders Meeting was a governance-heavy affair, with proposals flying faster than a biotech merger rumor.

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...